BioMarin Completes $4.8B Amicus Acquisition, Adds Two Lysosomal Disease Therapies
BioMarin completed its $4.8 billion acquisition of Amicus Therapeutics at $14.50 per share, securing two treatments for Fabry and Pompe diseases and US rights to Phase III FSGS candidate DMX-200. This deal expands BioMarin's rare disease portfolio and strengthens its commercial scale and manufacturing capabilities worldwide.
1. Acquisition Completed
BioMarin completed the all-cash acquisition of Amicus Therapeutics for $14.50 per share, valuing the transaction at nearly $4.8 billion and finalizing a deal announced in December 2025.
2. Expanded Treatment Portfolio
The deal brings Galafold for Fabry disease and the Pombiliti plus Opfolda combination for late-onset Pompe disease into BioMarin’s commercial lineup, both of which hold approvals in the US and multiple global markets.
3. FSGS Pipeline Addition
BioMarin gains US rights to DMX-200, an oral small molecule in Phase III trials for focal segmental glomerulosclerosis, further diversifying its rare disease pipeline.
4. Strategic Growth Impact
The acquisition strengthens BioMarin's global scale, commercial infrastructure, and in-house manufacturing, supporting the company’s goal to expand patient access and drive growth in rare disease therapeutics.